[Reuters] – Ariad Pharmaceuticals Inc, which has been struggling with safety concerns involving its only approved drug, said it agreed to add two directors backed by its second-largest investor Sarissa Capital Management to its board. Ariad shares rose n moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring […]
[Business Wire] – ARIAD Pharmaceuticals, Inc. today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors, effective immediately. moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring next, click here to view […]
[Business Wire] – ARIAD Pharmaceuticals, Inc. today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is […]
moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring next, click here to view […]
moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring next, click here to view […]
moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring next, click here to view […]
moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboardSee who ARIAD is hiring next, click here to view […]
[ACN Newswire] – By Jake KingOn the heels of ponatinib’s Priority Review announcement , Ariad Pharmaceuticals (NASDAQ:ARIA) reported 3Q financial results Wednesday, and on its related conference call emphasized the preparation … moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingShares of ARIAD Pharmaceuticals (NASDAQ:ARIA) were under pressure Tuesday following a downgrade from Oppenheimer, which lowered ARIA from Outperform to Perform with a $23 price target. ARIA … moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – In PropThink’s September 26th article on ARIAD Pharmaceuticals (NASDAQ:ARIA), titled Diagnostic Withdrawal Created Weakness in ARIA and an Opportunity for Investors, we wrote:ARIAD initiated … moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboard […]
